Comparative Pharmacology
Head-to-head clinical analysis: LARIN FE 1 20 versus MONO LINYAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARIN FE 1 20 versus MONO LINYAH.
LARIN FE 1/20 vs MONO-LINYAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LARIN FE 1/20 is a combination oral contraceptive containing ethinyl estradiol and norethindrone. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
Monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets per cycle.
10 mg orally once daily
None Documented
None Documented
Ethinyl estradiol: ~13 hours (range 7-20); norethindrone: ~8-11 hours. Steady-state reached in 5-7 days.
Terminal elimination half-life is 3–5 hours in adults; prolonged to 8–15 hours in renal impairment (CrCl <30 mL/min) and in neonates.
Renal (60% as metabolites, <10% unchanged); biliary/fecal (40%)
Predominantly renal as unchanged drug (≥90%); minor biliary/fecal (<5%).
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive